Tandem Diabetes Care (TNDM) closed at $20.07 on November 13, 2026, up 14.6% from the previous close, on volume of 4,077,481 shares (30-day average 2,411,598).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Seagull With Put Spread | 20-Nov-2615 P : 18 P : 25 C | 4,500 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Tandem jumps on FDA clearance of Tandem Mobi tubeless insulin pump
Seeking Alpha News (Fri, 13-Nov 11:47 AM ET)
Tandem Diabetes Care Receives FDA Clearance for Tandem Mobi
TipRanks (Fri, 13-Nov 8:58 AM ET)
Business Wire (Fri, 13-Nov 8:30 AM ET)
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
Business Wire (Thu, 12-Nov 8:30 AM ET)
Analysts’ Top Healthcare Picks: Voyager Therapeutics (VYGR), Evolent Health (EVH)
TipRanks (Mon, 9-Nov 11:30 AM ET)
Market Chameleon (Fri, 6-Nov 4:56 AM ET)
Tandem Diabetes Care Names Jeannette Bankes as President and Chief Executive Officer
Business Wire (Thu, 5-Nov 4:08 PM ET)
Tandem Diabetes Care Announces Third Quarter 2026 Financial Results
Business Wire (Thu, 5-Nov 4:05 PM ET)
Tandem Diabetes Care Announces Upcoming Conference Presentations
Business Wire (Fri, 30-Oct 4:05 PM ET)
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Business Wire (Thu, 1-Oct 4:05 PM ET)
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
Tandem Diabetes Care trades on the NASDAQ stock market under the symbol TNDM.
As of November 13, 2026, TNDM stock price climbed to $20.07 with 4,077,481 million shares trading.
TNDM has a beta of 0.11, meaning it tends to be less sensitive to market movements. TNDM has a correlation of 0.00 to the broad based SPY ETF.
TNDM has a market cap of $1.40 billion. This is considered a Small Cap stock.
Last quarter Tandem Diabetes Care reported $284 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $18 million and exceeded earnings estimates by $.15.
In the last 3 years, TNDM traded as high as $53.69 and as low as $9.98.
The top ETF exchange traded funds that TNDM belongs to (by Net Assets): IJR, VTI, IWM, VB, FESM.
TNDM has outperformed the market in the last year with a price return of +14.5% while the SPY ETF gained +13.4%. However, in the short term, TNDM had mixed performance relative to the market. It has underperformed in the last 3 months, returning -13.2% vs -2.8% return in SPY. But in the last 2 weeks, TNDM shares have fared better than the market returning +5.0% compared to SPY -0.2%.
TNDM support price is $16.57 and resistance is $18.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNDM shares will trade within this expected range on the day.
